Acorda Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 27.72 million compared to USD 33.51 million a year ago. Net loss was USD 8.89 million compared to USD 13.85 million a year ago. Basic loss per share from continuing operations was USD 7.16 compared to USD 11.17 a year ago. Diluted loss per share from continuing operations was USD 7.16 compared to USD 11.17 a year ago.
For the nine months, revenue was USD 79.65 million compared to USD 87.1 million a year ago. Net loss was USD 35.09 million compared to USD 85.06 million a year ago. Basic loss per share from continuing operations was USD 28.25 compared to USD 97.66 a year ago. Diluted loss per share from continuing operations was USD 28.25 compared to USD 97.66 a year ago.